Routine annual meeting filing with no immediate trading catalyst. The 1,500,000 share increase to the equity plan is standard for a pre-commercial biotech and does not signal any change in business outlook. Monitor for future equity grant disclosures to assess actual dilution.
Price Chart
Executive Summary
X4 Pharmaceuticals held its 2026 annual meeting on May 11, 2026, where stockholders approved an amendment to the 2017 Equity Incentive Plan adding 1,500,000 new shares for issuance, re-elected three Class III directors, ratified PwC as auditor, and approved say-on-pay. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, increasing authorized shares by 1,500,000.
- Three Class III directors (Gary J. Bridger, Françoise De Craecker, Michael S. Wyzga) were re-elected to serve until the 2029 annual meeting.
- PricewaterhouseCoopers LLP was ratified as independent auditor for FY 2026.
- Say-on-pay proposal for named executive officer compensation was approved on a non-binding advisory basis.
- As of the March 13, 2026 record date, 90,919,696 shares of common stock were outstanding and entitled to vote.
Financial Impact
No financial figures reported. The 1,500,000 share increase to the equity plan represents potential dilution of approximately 1.65% of outstanding shares (based on 90,919,696 shares outstanding), but no actual grants or dollar amounts are disclosed.
Risk Factors
- Potential dilution from future equity grants under the expanded plan, though no grants are disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001501697-26-000047 |
| Document: xfor-20260511.htm | 0001501697-26-000047 |
| Document: 0001501697-26-000047-index-headers.html | 0001501697-26-000047 |
| Document: 0001501697-26-000047-index.html | 0001501697-26-000047 |
| Document: 0001501697-26-000047.txt | 0001501697-26-000047 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.91 | awaiting T+20 | — | $3.25 (+11.68%) |
Oct 7, 2026 19d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.25 (+15.66%) |
Oct 1, 2026 25d ago | 144 | $2.83 | awaiting T+20 | — | $3.25 (+14.84%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.25 (−5.25%) |
Sep 8, 2026 6w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.25 (−7.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.25 (−22.99%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.25 (−24.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.25 (−11.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers